These results revealed that LY reversed the TGF-β1-induced activation of the fibroblasts and blocked the TGF-β/Smad signaling pathway in vitro, thus providing crucial prerequisites for relieving tumor fibrosis and the intrinsic immune resistance induced by the activated TGF-β signaling pathway. The gene discussed is TGFB1; the disease is neoplasm.